FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885183647> ?p ?o ?g. }

• W2885183647 endingPage "464" @default.
• W2885183647 startingPage "456" @default.
• W2885183647 abstract "To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed cabazitaxel effectiveness, health-related quality of life (HRQoL) and safety.CAPRISTANA was an international, observational cohort study examining cabazitaxel use for the treatment of patients with mCRPC. Effectiveness was assessed by overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF) and disease control rate. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P) and the three-level European Quality of Life questionnaire (EQ-5D-3L). Safety was assessed by adverse event (AE) reporting.A total of 189 patients were treated across 54 centres between April 2012 and June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% had an Eastern Cooperative Oncology Group performance status ≤1, and 60.1% had a Gleason score at diagnosis of ≥8. Patients received a median of 6 cabazitaxel cycles; 84.7% received cabazitaxel as second-line therapy. The median OS, PFS and TTF were 13.2, 5.6 and 4.4 months, respectively. Cabazitaxel led to disease control in 52.9% of patients. HRQoL was maintained (40.3%) or improved (32.2%) in 72.5% of patients based on total FACT-P scores. Interestingly, 53.6% of patients reported pain improvement and a further 21.2% maintained pain control based on FACT-P prostate cancer-specific pain scores. The most common treatment-related grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%).Patients in CAPRISTANA treated with cabazitaxel had similar disease outcomes and safety profiles compared with large phase III clinical trials. Most patients had maintained or improved HRQoL scores; >70% of patients had maintained or improved pain control." @default.
• W2885183647 created "2018-08-22" @default.
• W2885183647 creator A5001994148 @default.
• W2885183647 creator A5008329268 @default.
• W2885183647 creator A5022553675 @default.
• W2885183647 creator A5032858753 @default.
• W2885183647 creator A5033749771 @default.
• W2885183647 creator A5034858143 @default.
• W2885183647 creator A5040261282 @default.
• W2885183647 creator A5041524625 @default.
• W2885183647 creator A5049746160 @default.
• W2885183647 creator A5071855452 @default.
• W2885183647 creator A5075430152 @default.
• W2885183647 creator A5081756514 @default.
• W2885183647 creator A5086382821 @default.
• W2885183647 date "2018-09-16" @default.
• W2885183647 modified "2023-10-16" @default.
• W2885183647 title "An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)" @default.
• W2885183647 cites W1512031039 @default.
• W2885183647 cites W1757407923 @default.
• W2885183647 cites W1904433804 @default.
• W2885183647 cites W2004909463 @default.
• W2885183647 cites W2029087193 @default.
• W2885183647 cites W2080439368 @default.
• W2885183647 cites W2094993869 @default.
• W2885183647 cites W2101713088 @default.
• W2885183647 cites W2103959341 @default.
• W2885183647 cites W2105258029 @default.
• W2885183647 cites W2110534364 @default.
• W2885183647 cites W2114282601 @default.
• W2885183647 cites W2120292596 @default.
• W2885183647 cites W2123526148 @default.
• W2885183647 cites W2140665438 @default.
• W2885183647 cites W2144439788 @default.
• W2885183647 cites W2144827656 @default.
• W2885183647 cites W2148643283 @default.
• W2885183647 cites W2473786944 @default.
• W2885183647 cites W2748229172 @default.
• W2885183647 cites W2748586176 @default.
• W2885183647 doi "https://doi.org/10.1111/bju.14509" @default.
• W2885183647 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7379594" @default.
• W2885183647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30098093" @default.
• W2885183647 hasPublicationYear "2018" @default.
• W2885183647 type Work @default.
• W2885183647 sameAs 2885183647 @default.
• W2885183647 citedByCount "14" @default.
• W2885183647 countsByYear W28851836472019 @default.
• W2885183647 countsByYear W28851836472020 @default.
• W2885183647 countsByYear W28851836472021 @default.
• W2885183647 countsByYear W28851836472023 @default.
• W2885183647 crossrefType "journal-article" @default.
• W2885183647 hasAuthorship W2885183647A5001994148 @default.
• W2885183647 hasAuthorship W2885183647A5008329268 @default.
• W2885183647 hasAuthorship W2885183647A5022553675 @default.
• W2885183647 hasAuthorship W2885183647A5032858753 @default.
• W2885183647 hasAuthorship W2885183647A5033749771 @default.
• W2885183647 hasAuthorship W2885183647A5034858143 @default.
• W2885183647 hasAuthorship W2885183647A5040261282 @default.
• W2885183647 hasAuthorship W2885183647A5041524625 @default.
• W2885183647 hasAuthorship W2885183647A5049746160 @default.
• W2885183647 hasAuthorship W2885183647A5071855452 @default.
• W2885183647 hasAuthorship W2885183647A5075430152 @default.
• W2885183647 hasAuthorship W2885183647A5081756514 @default.
• W2885183647 hasAuthorship W2885183647A5086382821 @default.
• W2885183647 hasBestOaLocation W28851836471 @default.
• W2885183647 hasConcept C121608353 @default.
• W2885183647 hasConcept C126322002 @default.
• W2885183647 hasConcept C143998085 @default.
• W2885183647 hasConcept C159110408 @default.
• W2885183647 hasConcept C197934379 @default.
• W2885183647 hasConcept C2777899217 @default.
• W2885183647 hasConcept C2778971682 @default.
• W2885183647 hasConcept C2779951463 @default.
• W2885183647 hasConcept C2780192828 @default.
• W2885183647 hasConcept C2781190966 @default.
• W2885183647 hasConcept C71924100 @default.
• W2885183647 hasConceptScore W2885183647C121608353 @default.
• W2885183647 hasConceptScore W2885183647C126322002 @default.
• W2885183647 hasConceptScore W2885183647C143998085 @default.
• W2885183647 hasConceptScore W2885183647C159110408 @default.
• W2885183647 hasConceptScore W2885183647C197934379 @default.
• W2885183647 hasConceptScore W2885183647C2777899217 @default.
• W2885183647 hasConceptScore W2885183647C2778971682 @default.
• W2885183647 hasConceptScore W2885183647C2779951463 @default.
• W2885183647 hasConceptScore W2885183647C2780192828 @default.
• W2885183647 hasConceptScore W2885183647C2781190966 @default.
• W2885183647 hasConceptScore W2885183647C71924100 @default.
• W2885183647 hasFunder F4320307781 @default.
• W2885183647 hasIssue "3" @default.
• W2885183647 hasLocation W28851836471 @default.
• W2885183647 hasLocation W28851836472 @default.
• W2885183647 hasLocation W28851836473 @default.
• W2885183647 hasLocation W28851836474 @default.
• W2885183647 hasLocation W28851836475 @default.
• W2885183647 hasOpenAccess W2885183647 @default.
• W2885183647 hasPrimaryLocation W28851836471 @default.
• W2885183647 hasRelatedWork W122177069 @default.
• W2885183647 hasRelatedWork W1543388821 @default.

• next